ADM Tronics- Biotechrakete noch bezahlbar ! - 500 Beiträge pro Seite

[Nokian]

Nachdem Admt am Donnerstag um 72 % gestiegen ist, fiel die Aktie am Freitag um 2 %, das kursziel bleibt bei 2 Euro, aktuell 60 cent !
Die Firma schreibt schwarze Zahlen ! Kursziel von heiko thieme im brichtboard übrigens 3 euro !

[heckemini]

Hi,

ADMT wird an der OTC gehandelt. Sie hat eine Marktkapitalisierung von 28 Mio us-$. Allerdings noch nicht ganz in den schwarzen Zahlen. Denke aber durchaus aussichtsreich, da sie mehr Chemische Produkte herstellt und vertreibt. Also nicht direkt des Risikos der Forschungen im Bereich Biotech unterliegt. Ich denke hier sollte man wirklich mal ein Auge drauf werfen und vielleicht eine kleine Menge ordern. Denn hier könnte sehr schnell mehr als ein Verdoppler drinnen sein. Man sollte allerdings immer noch das Risiko der OTC im Auge behalten!

Ich kopiere hier mal kurz die Fundamentalen Daten dieser Aktie rein:ADM Tronics Unlimited is a manufacturer and engineering concern whose principal lines of business are the production and sale of chemical products and the manufacturing and sale of medical devices. For the six months ended 9/99, revenues rose 37% to $1.4 million. Net loss fell 67% to $80 thousand. Revenues reflect company`s increased medical electronics activities and chemical revenues. Lower loss reflects increased gross profit margins due to product mix


ALSO: Der Netto Verlust fiel um 67% hört sich sehr positiv an, auf $80.000. Ausstehende Aktien haben wir 47,4 Mio. also sind wir noch knapp in der Verlustzone!



silke

[heckemini]

Hallo nokian,

sag mal der Wert wird doch nur an der OTC gehandelt...oder? Haste zufällig die WKN zur Hand, denn bei Consors benötigt man ja sowas!

Danke im Voraus

silke

[heckemini]

Ich nochmal,

hier noch der neueste Quartalsbericht. Weißt Du warum die Margen im letzten Quratal gesunken sind?!

good luck
silke--------------------------------------------------------------------------------
February 14, 2000
ADM TRONICS UNLIMITED INC/DE (ADMT)
Quarterly Report (SEC form 10QSB)
Management`s Discussion and Analysis of Financial Condition and Results of Operations
Liquidity and Capital Resources

At December 31, 1999 the Company had cash and equivalents of $299,658 as compared to $496,405 at March 31, 1999. This decrease was the result of cash flows used in operating and investing activities offset by cash provided by financing activities.

Operating Activities

Net cash flows used increased $29,903 to ($334,601) for the nine months ended December 31, 1999 as compared to ($304,698) for the nine months ended December 31, 1998. This increase was primarily due to a net decrease in operating assets and liabilities offset by higher depreciation.

Investing Activities

Investing activities consisted of cash used for the Needleeater acquisition of $48,820, purchases of property and equipment of $14,339 and additional net net borrowings by an officer of the Company of $700.

Financing Activities

The Company borrowed $304,831 of which $300,000 represents a new line of credit with the Company`s primary bank. The Company repaid $104,518 in notes payable primarily paying-off the old line of credit.

The Company does not have any material external sources of liquidity or unused sources of funds.



Results of Operations Quarter Ended December 31, 1999

Revenues

Revenues were $647,480 in 1999 as compared to $631,405 in 1998 representing an increase of $16,075 or 2.5%. Revenues from the Company`s medical elec- tronics activities increased $1,570 and chemical revenues increased $14,505 over revenues for 1998.

Gross Profit

Gross profit of $197,268 in 1999 was $144,041, or 42% below the gross profit of $341,309 in 1998. Gross profit was 30.5% of revenues in 1999 as compared with 54% of revenues in 1998. The reduction in gross profit margin was due primarily to the product mix of sales with increased ssales of products with a lower gross profit margin.

Operating Income (Loss)

Operating loss of $222,119 in 1999 was $112,440 above the operating loss of $109,679 in 1998. Selling general and administrative expenses decreased by $31,601.

Other Income

Other income of $3,957 in 1999 decreased by $4,962, or 55.6%, from $8,919 in 1998, principally due to a decrease in interest income from reduced amounts invested.


Results of Operations Nine Months Ended December 31, 1999

Revenues

Revenues were $2,018,168 in 1999 as compared to $1,632,508 in 1998 representing an increase of $385,660 or 19.1%. Revenues from the Company`s medical elec- tronics activities increased $303,493 and chemical revenues increased $82,167.

Gross Profit

Gross profit of $940,872 in 1999 was $95,877 or 10.2% higher than the gross profit of $844,995 in 1998. Gross profit was 47% of revenues in 1999 as compared with 52% of revenues in 1998. The lower gross profit percentage was due to the product mix of sales with higher sales volume of products with a lower gross profit margin.

Operating Income (Loss)

Operating loss of $329,860 in 1999 was $39,278 lower than the operating loss of $369,138 in 1998. Selling, general and administrative expenses increased by $56,599, primarily due to an increase in payroll for sales personnel.

Other Income

Other income of $31,306 in 1999 increased $2,079 from $29,227 in 1998, primarily due to the collection of rent from a sub-tenant offset by a decrease in interest income from reduced amounts invested.







Item 6 Exhibits and reports on Form 8-K


(a) Exhibits

27. Financial Data Schedule

(b) Not applicable